Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has named Reshma Kewalramani as its new chief medical officer, it was reported yesterday.
Kewalramani succeeds Jeffrey Chodakewitz, who will remain at the company as a senior advisor until early 2019.
Prior to joining the biotech, Kewalramani served as vice president, head of the US medical organisation at Amgen, where she spent 12 years in various capacities.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera